ReviewCurrent diabetes reports2008
Fatty liver, insulin resistance, and dyslipidemia.
Review in Current diabetes reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 142 citations in OpenAlex.
- Nocturnal Hypoxic Exposure Combined with Two-Week Hypoxic Training and Calorie Restriction Improves Lipid Profile and Body Composition in Men with Obesity-Related Hypercholesterolemia: A Controlled Intervention Study.International journal of molecular sciences · 2026Trial
- Hypoxic Training with Calorie Restriction Improves Lipid Profile and Body Composition in Men with Obesity-Related Hypercholesterolemia: A Controlled Intervention Study.International journal of molecular sciences · 2025Trial
- Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD.Nutrients · 2014Trial
- Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients.Diabetes care · 2012Trial
- Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients.Diabetes care · 2009Trial
- Article
- Unraveling Hippocampal and Prefrontal Cortex Alterations in Experimental Type 1 and Type 2 Diabetes: A 100-Day Exploration of Biochemical and Behavioral-Cognitive Dysfunction.Molecular neurobiology · 2026Article
- Diagnostic and therapeutic potential of serum fatty acids in hyperlipidemia: evidence from three cohorts of patients with coronary atherosclerotic heart disease.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Association between the ApoB/ApoA1 ratio and both the severity and mortality of metabolic dysfunction-associated fatty liver disease.BMC gastroenterology · 2025Article
- Lipid Biochemistry and its Role in Human Diseases.Current medicinal chemistry · 2025Review
- Association of dietary inflammatory index on all-cause and cardiovascular mortality in U.S. adults with metabolic dysfunction associated steatotic liver disease.Frontiers in nutrition · 2025Article
- Association of changes and cumulative measures of triglyceride-glucose index-body mass index with hypertension risk: a prospective cohort study.BMC public health · 2024Article
- Quercetin prevents rats from type 1 diabetic liver damage by inhibiting TGF-ꞵ/apelin gene expression.Current research in pharmacology and drug discovery · 2024Article
- Association of nonalcoholic fatty liver disease and carotid media-intima thickness: A systematic review and a meta-analysis.Health science reports · 2023Article
- Differentially Expressed Genes in Response to a Squalene-Supplemented Diet Are Accurate Discriminants of Porcine Non-Alcoholic Steatohepatitis.International journal of molecular sciences · 2023Article
- Article
- From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications.Biomedicines · 2023Review
- Antidiabetic activity ofFrontiers in pharmacology · 2023Article
- Non-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology.Middle East journal of digestive diseases · 2022Review
- Beneficial Effect ofTheScientificWorldJournal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After recently being recognized as a feature of the metabolic syndrome, fatty liver has evolved as a key player in the pathogenesis of dyslipidemia. Development of nonalcoholic fatty liver disease comes from an imbalance between the influx and production of fatty acids and the use of fatty acids for oxidation or secretion as very low density lipoprotein (VLDL) triglycerides. Previously, we have shown a strong relationship between increased liver fat and overproduction of large VLDL particles. We observed recently that in patients with high liver fat, insulin was unable to regulate VLDL production. The result is increased concentrations of VLDL particles in the circulation. Consequently, changes are seen in the metabolism of other lipoproteins that interact with VLDL particles, the net result being decreased high-density lipoprotein cholesterol and increased formation of small, dense low-density lipoprotein. In this article, we review recent findings on the development of fatty liver and its role in the diabetic dyslipidemia pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.